Canephron® Uno is used in cases of mild symptoms of urinary tract inflammation, such as:

  • frequent urination
  • pain/burning/stinging during urination
  • increased/urgent need to urinate(1)(2)
 

Urgency

Frequent Urination

Suprapubic pain

 

At the same time, it can be used for flushing the urinary system, with the aim of reducing the deposition of kidney stones.(1)

Canephron® Uno has analgesic, anti-inflammatory, and antispasmodic effects, while it also inhibits the adhesion of Escherichia coli.(2) E. coli is the bacterium responsible for approximately 80% of uncomplicated cystitis cases worldwide.(2)

To Canephron® Uno is a plant-based medicine, which is a combination of three medicinal plants.

Specifically:

 

Centaury Herb

Lovage Root

Rosemary Leaves(1)

 

Dosage

  • 1 tablet every 8 hours. Adequate fluid intake is required.(1)
  • Canephron® Uno is intended for adults and children aged 12 years and older.(1)

For more information, please read the Canephron® Uno information leaflet.

THE MINISTRY OF HEALTH AND THE NATIONAL ORGANIZATION FOR MEDICINES RECOMMEND: READ THE INSTRUCTIONS LEAFLET CAREFULLY - CONSULT YOUR DOCTOR OR PHARMACIST.

A non-prescription herbal medicine for mild symptoms of urinary tract inflammation and its flushing. It should not be used in children under 12 years of age. Contraindicated in cases of hypersensitivity to the ingredients, anethole or plants of the Apiaceae family, peptic ulcers, fructose or galactose intolerance, glucose-galactose malabsorption, sucrase-isomaltase or lactase deficiency, and breastfeeding. Administration in individuals under 18 years of age, during pregnancy, or for more than 2 weeks requires a doctor’s recommendation. If symptoms persist for more than 3 days, consult a doctor. It should not be taken in cases of edema due to heart or kidney dysfunction or when medical advice suggests a reduced fluid intake. Each tablet contains, on average, 0.3 grams of carbohydrates.

References

1) Canephron® Uno SPC
2) Naber et al. (2018), Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections in Women: A Double-Blind, Parallel-Group, Randomized, Multicentre, Non-Inferiority Phase III Trial

CAN/DPM/WBC/11_2024/02